Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe in Homozygous Familial Hypercholesterolemia
NCT03884452Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- May 2000
- Primary completion
- May 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe in homozygous familial hypercholesterolemia (HoFH), sponsored by Organon & Co. Primary endpoints: Low Density Lipoprotein Cholesterol measured directly at 12 weeks and Adverse Events at 12 weeks. Started May 2000; status: completed.
02
Drugs
ezetimibe
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT03884452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884452.